Company Overview and News

2
Simon Opens Hotel at Southdale Center, Boosts Redevelopment

2018-09-19 zacks
Retail REIT Simon Property Group, Inc. (SPG - Free Report) is making every effort to enhance the value of its properties. Recently, the company, along with Noble Investment Group, announced the inauguration of the Homewood Suites by Hilton Edina Minneapolis. The hotel is part of Southdale Center's mixed-use development. The addition of this hotel to the Southdale Center's mixed-use development is a strategic fit.
GIS SHAK UNP SPG RGRNF RGS

 
Beyer to lead Regis

2018-09-17 businessnews.com.au
Former Mt Gibson Iron boss Jim Beyer will take the reins as managing director of Regis Resources next month, while director James Mactier will take over as chair, after executive chairman Mark Clark announced his resignation.
RRL RGRNF

2
Energy sector lifts ASX to higher week

2018-09-14 theage.com.au
Australian shares have rebounded from last week's $50 billion fall to close the week higher despite some of the major financial stocks weighing the index.
WOPEF RIO RIO SNMYF EVN IAG OGFGY RSG BEPTF RTPPF GALXF SUN RMGGF RTNTF CAHPF MS IAUGY WTCHF SNMCY WPL RGRNF BCHEY WOPEY BPT GXY IAUGF RMGGY RIO RRL OGFGF ORG

2
Energy sector lifts ASX to higher week

2018-09-14 smh.com.au
Australian shares have rebounded from last week's $50 billion fall to close the week higher despite some of the major financial stocks weighing the index.
WOPEF RIO RIO SNMYF EVN IAG OGFGY RSG BEPTF RTPPF GALXF SUN RMGGF RTNTF CAHPF MS IAUGY WTCHF SNMCY WPL RGRNF BCHEY WOPEY BPT GXY IAUGF RMGGY RIO RRL OGFGF ORG

 
Position Close Update: Regis Corporation

2018-09-12 seekingalpha
While RGS still earns a bottom-quintile 3% return on invested capital, its valuation no longer presents attractive risk/reward given the improving fundamentals.
RGRNF RGS

 
Regis Resources achieves record gold production and profit in 2018

2018-08-28 australianmining.com.au
Perth-based gold-nickel explorer Regis Resources has announced its results for the 2018 financial year (FY2018), posting new company records for gold production and net profit after tax.
RRL RGRNF

 
Regis Corporation 2018 Q4 - Results - Earnings Call Slides

2018-08-22 seekingalpha
The following slide deck was published by Regis Corporation in conjunction with their 2018 Q4 earnings call.
RGRNF RGS

 
Regis Corporation (RGS) CEO Hugh Sawyer on Q4 2018 Results - Earnings Call Transcript

2018-08-21 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Regis Corporation Fiscal 2018 Fourth Quarter and Year End Earnings Call. My name is Cecilia, and I will be your conference facilitator today. At this time, all participants are in a listen-only mode. Following management's presentation, we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded for playback and will be available by approximately 12:00 PM Eastern Time today.
RGRNF RGS

2
Growing US-China trade tensions push ASX lower

2018-08-07 theage.com.au
The Australian sharemarket has fallen on the back poor commodity prices as the escalating trade war between Washington and Beijing stokes metal demand concerns in China.
WOPEF RIO BLT RIO NHPEF BHPBF WPL RGRNF OGFGY BCHEY WOPEY BEPTF BPT RTPPF BHP RIO RRL RTNTF BBL BHP OGFGF BHPLF ORG

2
Growing US-China trade tensions push ASX lower

2018-08-07 smh.com.au
The Australian sharemarket has fallen on the back poor commodity prices as the escalating trade war between Washington and Beijing stokes metal demand concerns in China.
WOPEF RIO BLT RIO NHPEF BHPBF WPL RGRNF OGFGY BCHEY WOPEY BEPTF BPT RTPPF BHP RIO RRL RTNTF BBL BHP OGFGF BHPLF ORG

 
WA listed companies reach highest value since 2011

2018-08-06 australianmining.com.au
Deloitte’s latest WA Index has shown that the value of Western Australia-based listed companies has jumped by 26.8 per cent to $193.5 billion during the 2018 financial year, the highest level since May 2011.
PLS WOPEF PILBF BWP TGN LYSCF EOHDF MALRY IGO IIDDY WPL RGRNF MIN AMSLF WOPEY AUZ EHL LYSDY RRL MALRF

1
Diggers and Dealers Mining Forum gold plays to make up 21% of presenters

2018-08-05 proactiveinvestors.com.au
Diggers and Dealers Mining Forum 2018 will welcome a pack of gold plays to the stage this week to speak about their companies and the precious metal. Here’s who’s going.
ELKMF OCANF PILBF RMS EVN GCY SCEXF SNDFY WAF NST DCN AU IGO AULGF RSG OGC GOR LONCF MSR RMGGF SFR SBM AGG CAHPF PLS WFRSF IIDDY RGRNF ORG PNR LN NESRF SFRRF RMGGY RRL OGDCF NHRNY CANWF RMLRF SAR

 
Regis plans $29m expansion

2018-08-03 businessnews.com.au
Regis Resources has approved a $29.4 million expansion at its Duketon gold project, which is expected to add 570,000 ounces over a five-year mine life.
RRL RGRNF

 
Perseus Mining has major shareholder increase stake

2018-08-03 proactiveinvestors.com.au
Perseus Mining Ltd (ASX:PRU) has had substantial shareholder, Van Eck Associates Corporation, increase its holding in the company to 6.01% from 5.01%.
EVN RRL NST PMNXF CAHPF NHRNY PRU PRU RGRNF NESRF GDXJ

 
Regis Resources approves underground development at Rosemont Gold Mine

2018-08-03 proactiveinvestors.com.au
Regis Resources Ltd (ASX:RRL) has received board approval to develop an underground gold mine directly below the operating open pit at its Rosemont project north of Laverton in Western Australia.
RRL EGS EGDD RGRNF ESGFF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: Q8059N120